MUC1 is an inclusion criterion in 3 clinical trials for breast carcinoma, of which 3 are open and 0 are closed. Of the trials that contain MUC1 status and breast carcinoma as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 1/phase 2 (1 open) [4].

MUC1 is an inclusion criterion in 3 clinical trials for non-small cell lung carcinoma, of which 2 are open and 1 is closed. Of the trials that contain MUC1 status and non-small cell lung carcinoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2/phase 3 (0 open) [4].

MUC1 is an inclusion criterion in 2 clinical trials for fallopian tube carcinoma, of which 1 is open and 1 is closed. Of the trials that contain MUC1 status and fallopian tube carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (0 open) [4].

MUC1 is an inclusion criterion in 2 clinical trials for hepatocellular carcinoma, of which 2 are open and 0 are closed. Of the trials that contain MUC1 status and hepatocellular carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [4].

MUC1 is an inclusion criterion in 2 clinical trials for ovarian carcinoma, of which 1 is open and 1 is closed. Of the trials that contain MUC1 status and ovarian carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (0 open) [4].

MUC1 is an inclusion criterion in 1 clinical trial for cancer, of which 1 is open and 0 are closed. Of the trial that contains MUC1 status and cancer as inclusion criteria, 1 is phase 1 (1 open) [4].

MUC1 is an inclusion criterion in 1 clinical trial for endometrial endometrioid adenocarcinoma, of which 0 are open and 1 is closed. Of the trial that contains MUC1 status and endometrial endometrioid adenocarcinoma as inclusion criteria, 1 is phase 2 (0 open) [4].

MUC1 is an inclusion criterion in 1 clinical trial for endometrial serous adenocarcinoma, of which 0 are open and 1 is closed. Of the trial that contains MUC1 status and endometrial serous adenocarcinoma as inclusion criteria, 1 is phase 2 (0 open) [4].

MUC1 is an inclusion criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains MUC1 status and malignant solid tumor as inclusion criteria, 1 is phase 1 (1 open) [4].

MUC1 is an inclusion criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains MUC1 status and multiple myeloma as inclusion criteria, 1 is phase 1 (1 open) [4].

MUC1 is an inclusion criterion in 1 clinical trial for pancreatic adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains MUC1 status and pancreatic adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].

MUC1 is an inclusion criterion in 1 clinical trial for pancreatic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MUC1 status and pancreatic carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

MUC1 is an inclusion criterion in 1 clinical trial for primary peritoneal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains MUC1 status and primary peritoneal carcinoma as inclusion criteria, 1 is phase 2 (0 open) [4].

MUC1 is an inclusion criterion in 1 clinical trial for uterine corpus carcinosarcoma, of which 0 are open and 1 is closed. Of the trial that contains MUC1 status and uterine corpus carcinosarcoma as inclusion criteria, 1 is phase 2 (0 open) [4].